The Rise of Alternative (Non-) Antibody Scaffolds Therapeutics
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 438
Special Issue Editor
Interests: drug development; biological drugs; antibody fragments; immunomodulators
Special Issue Information
Dear Colleagues,
The development of high-affinity antibodies has proved to be a valuable form of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Nevertheless, antibody-based therapeutics still face several challenges, limiting their widespread application, including high production costs, limited stability, suboptimal format for targeted payload delivery or poor tissue penetration. Limitations on whole antibodies application have led to the development and study of various antibody fragments and antibody-like scaffold proteins as alternatives for different therapeutic applications.
This Special Issue will focus on the development and application of antibody fragments (e.g., single-chain variable fragments, single domain antibody fragments) and nonantibody binding proteins (e.g., knottins, Kunitz domains, etc.) to the treatment of infections, autoimmune conditions, cancer, and neurological diseases.
Dr. Fernandes Joao C.
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- drug candidates
- targeted drug delivery
- single domain antibodies
- antigen-binding fragments
- single chain variable fragments
- antibody mimics
- diabodies
- bispecific
- preclinical development
